Pablo Redruello-Guerrero

Dr. Pablo Redruello-Guerrero

Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Castille-Leon, Spain
+1
orcid
MD, PhD student

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
MRMario Rivera-Izquierdo
Mario Rivera-Izquierdo
Antonio Jesús Láinez-Ramos-BossiniAntonio Jesús Láinez-Ramos-Bossini
Antonio Jesús Láinez-Ramos-Bossini
CRCarlos Rivera-Izquierdo
Carlos Rivera-Izquierdo
JLJairo López-Gómez
Jairo López-Gómez
NMNicolás Francisco Fernández Martínez
Nicolás Francisco Fernández Martínez
EJEladio Jiménez-Mejías
Eladio Jiménez-Mejías
Carbapenemase-producing Enterobacterales (CPE) are significant contributors to the global public health threat of antimicrobial resistance. OXA-48-like enzymes and their variants are unique carbapenemases with low or null hydrolytic activity toward carbapenems but no intrinsic activity against expanded-spectrum cephalosporins. CPEs have been classified by the WHO as high-priority pathogens given their association with morbidity and mortality and the scarce number of effective antibiotic treatments. In Spain, the frequency of OXA-48 CPE outbreaks is higher than in other European countries, representing the major resistance mechanism of CPEs. Horizontal transfer of plasmids and poor effective antibiotic treatment are additional threats to the correct prevention and control of these hospital outbreaks. One of the most important risk factors is antibiotic pressure, specifically carbapenem overuse. We explored the use of these antibiotics in Spain and analyzed the frequency, characteristics and prevention of CPE outbreaks. Future antibiotic stewardship programs along with specific preventive measures in hospitalized patients must be reinforced and updated in Spain.

19 September 2022 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
Pablo Redruello-GuerreroPablo Redruello-Guerrero
Pablo Redruello-Guerrero
MRMario Rivera-Izquierdo
Mario Rivera-Izquierdo
CJCarmen Jiménez-Gutiérrez
Carmen Jiménez-Gutiérrez
ALAntonio Jesús Láinez-Ramos-Bossini
Antonio Jesús Láinez-Ramos-Bossini
RYRubén Yela
Rubén Yela
ILIgnacio López-Marín
Ignacio López-Marín
Purpose: Monofocal intraocular lenses (IOLs) used in cataract surgery are designed to improve visual acuity (VA). The available evidence of new monofocal IOLs” functional benefits is limited. The aim of this meta-analysis was to analyze the improvement in VA using Tecnis Eyhance monofocal IOLs compared to standard monofocal IOLs Tecnis ZCB00. Methods: MEDLINE, Web of Science and Scopus were searched for studies assessing improvement in intermediate VA using Tecnis Eyhance IOLs versus Tecnis ZCB00 IOLs. Studies evaluating post-operative VA in patients who underwent cataract surgery were selected. This meta-analysis followed PRISMA guidelines and was registered in PROSPERO. The Cochrane Risk of Bias Tool 2.0. was used to assess the methodological quality of the included studies, risk of selection bias and comparability of cohorts and outcomes. Results: The search resulted in 1153 articles. Five studies met the inclusion criteria and were included in the meta-analysis. A total of 604 eyes were evaluated, of which 309 received Tecnis Eyhance IOLs and 295 were implanted with Tecnis ZCB00 IOLs. Mean binocular distant-corrected intermediate VA with Tecnis Eyhance IOLs at 2 weeks-1 month showed a significant difference of −0,21 logMAR, p < 0.001; and mean binocular distance-corrected intermediate VA with Tecnis Eyhance IOLs at 6 months showed a significant difference of −0,11 logMAR, p < 0.001. Conclusion: Near VA could not be assessed in this meta-analysis as it was measured in very few studies. Preliminary pooled evidence indicates that intermediate VA improved with Tecnis Eyhance IOLs. Further studies evaluating near VA and with longer follow-up are still necessary.

1 December 2024 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
Pablo Redruello-GuerreroPablo Redruello-Guerrero
Pablo Redruello-Guerrero
PCPaula Córdoba-Peláez
Paula Córdoba-Peláez
Antonio Jesús Láinez-Ramos-BossiniAntonio Jesús Láinez-Ramos-Bossini
Antonio Jesús Láinez-Ramos-Bossini
MRMario Rivera-Izquierdo
Mario Rivera-Izquierdo
CMCristina Mesas
Cristina Mesas
GPGloria Perazzoli
Gloria Perazzoli
Background: Liposomal Doxorubicin (Doxil®) was one of the first nanoformulations approved for the treatment of solid tumors. Although there is already extensive experience in its use for different tumors, there is currently no grouped evidence of its therapeutic benefits in non-small cell lung cancer (NSCLC). A systematic review of the literature was performed on the therapeutic effectiveness and benefits of Liposomal Doxil® in NSCLC. Methods: A total of 1022 articles were identified in publications up to 2020 (MEDLINE, Cochrane, Web of Science Core Collection and Scopus). After applying inclusion criteria, the number was restricted to 114, of which 48 assays, including in vitro (n=20) and in vivo (animals, n=35 and humans, n=6) studies, were selected. Results: The maximum inhibitory concentration (IC50), tumor growth inhibition rate, response and survival rates were the main indices for evaluating the efficacy and effectiveness of Liposomal DOX. These have shown clear benefits both in vitro and in vivo, improving the IC50 of free DOX or untargeted liposomes, depending on their size, administration, or targeting. Conclusion: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.

1 July 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
Pablo Redruello-GuerreroPablo Redruello-Guerrero
Pablo Redruello-Guerrero
MGMaría Gómez-Tomás
María Gómez-Tomás
TSTomas Rechi Sierra
Tomas Rechi Sierra
LSLaura Molinero Sicilia
Laura Molinero Sicilia
NGNadia Galindo-Cabello
Nadia Galindo-Cabello
Salvador Pastor-IdoateSalvador Pastor-Idoate
Salvador Pastor-Idoate
Retinal detachment (RD) is a serious clinical condition that significantly impacts patients’ quality of life. Its management involves considering several clinical factors that may affect the therapeutic approach. Inflammatory complications can affect visual recovery, long-term outcomes, and prognosis. Understanding the underlying inflammatory mechanisms is key to improving personalized medicine and optimizing therapeutic approaches to management. This review comprehensively searched scientific databases (Medline, Web of Science, and Scopus), considering clinical and experimental studies published between 1999 and 2025. Specific MeSH terms and predefined inclusion and exclusion criteria were used to select the most relevant papers. A total of 140 studies were analyzed. The findings were analyzed qualitatively and illustrated with images from clinical practice. Several studies have demonstrated the critical role of cytokines in retinal inflammation, highlighting their importance in regulating the immune response following RD. In addition, oxidative stress, apoptotic mechanisms, and glia activation, particularly Müller cells and microglia, have been identified as crucial elements in the progression of retinal damage. In this sense, inflammation poses significant clinical challenges that require more effective therapeutic strategies. In conclusion, this review differs from previous literature by emphasizing the translational implications of inflammatory mechanisms in RD and by comparing experimental and clinical data. The management of RD should consider not only surgical aspects, but also modulation of the inflammatory response to improve visual outcomes and prevent long-term complications.

27 November 2020 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
Pablo Redruello-GuerreroPablo Redruello-Guerrero
Pablo Redruello-Guerrero
GPGloria Perazzoli
Gloria Perazzoli
ACAna Cepero
Ana Cepero
FQFrancisco Quiñonero
Francisco Quiñonero
CMCristina Mesas
Cristina Mesas
JPJose Prados
Jose Prados
Pancreatic ductal adenocarcinoma (PDA) has one of the worst prognosis and higher mortality among most cancers. The diagnosis of PDA is frequently delayed due to a lack of specific biomarkers, and the efficacy of current chemotherapeutic drugs is limited. Moreover, chemotherapy is generally applied in advanced stages, where metastatic spread has already occurred. Nanotechnologybased systems are allowing to advance in the diagnosis and treatment of PDA. New nanoformulations have shown to improve the activity of conventional chemotherapeutic agents, such as gemcitabine, and new antitumor drugs, protecting them from degradation, improving their selectivity, solubility and bioavailability, and reducing their side effects. Moreover, the design of nanocarriers represents a new way to overcome drug resistance, which requires a comprehensive understanding of the tumor microenvironment of PDA. This article reviews the current perspectives, based on nanomedicine, to address the limitations of pancreatic cancer treatment, and the futures lines of research to progress in the control of this disease.

26 June 2022 in Infection
Verified
Journal Article
Open access
PDF file
MRMario Rivera-Izquierdo
Mario Rivera-Izquierdo
MGMaría Dolores Galicia-García
María Dolores Galicia-García
Antonio Jesús Láinez-Ramos-BossiniAntonio Jesús Láinez-Ramos-Bossini
Antonio Jesús Láinez-Ramos-Bossini
Pablo Redruello-GuerreroPablo Redruello-Guerrero
Pablo Redruello-Guerrero
NMNicolás Francisco Fernández Martínez
Nicolás Francisco Fernández Martínez
Background: Listeriosis presents high rates of mortality but prognostic factors for early prevention are not well established. The aim of this study was to analyse factors associated with in-hospital and early mortality of adults after recovery from severe infection caused by Listeria monocytogenes. Methods: All cases of listeriosis notified in the province of Granada from January 2005 to December 2021, including 9 centres, were included. Only laboratory confirmed non-neonatal cases were considered. Follow-up was conducted by accessing medical records and epidemiological data. Bivariate and multivariate analyses were conducted to detect potential risk factors associated to in-hospital mortality, 1-year, and 5-year early death after recovery. Multivariate Cox regression models were performed. A total of 206 patients were identified. Results: The mean age was 62.6 years (sd, 18.8). A high frequency of comorbidities (88.3%) was observed, and 42 patients (20.4%) died during hospitalisation. Of the patients who recovered from acute infection, 26 (15.9%) died during the following year and 47 (28.7%) died during the following 5 years. The main factors associated with early mortality after recovery were age (HR: 1.03; 95% CI 1.02–1.07), diabetes mellitus (HR 1.86, 95% CI 1.01–3.44), chronic kidney disease (HR 3.96, 95% CI 1.87–8.38), liver disease (HR 3.62, 95% CI 1.64–8.51), and cancer (HR 3.76, 95% CI 1.90–7.46). Conclusion: Listeriosis is associated with high early post-recovery mortality. Our study describes the main prognostic factors, which may help to improve preventive follow-up strategies of adults with severe listeriosis.